Effect of Erector Spinae Plane Block Applied to Painful Herpes Zoster Patients Who Failed to Respond to Pregabalin Treatment on Immunological Marker Levels and Postherpetic Neuralgia Incidence Rate Authors: Gülçin Büyükbezirci, Numan Demiralp, Sevgi Keles, Resul Yılmaz, Şule Arıcan, Sema Tuncer Uzun, Ruhiye Reisli, İsmail Reisli Published: 2026 ABSTRACT AbstractPurposePostherpetic neuralgia (PHN) is one of the most debilitating complications of herpes zoster and represents a major cause of chronic neuropathic pain. Increasing evidence suggests that immune dysregulation plays a critical role in neuropathic pain development. This study aimed to investigate the effects of the erector spinae plane (ESP) block on PHN development and immunological marker levels in herpes zoster patients who did not respond to pregabalin therapy.Patients and MethodsThis prospective, controlled, single‑blind, non-randomized study included 30 patients with herpes zoster. Pregabalin therapy was initiated in all patients. Patients whose pain was adequately controlled with pregabalin were assigned to Group I, whereas patients with insufficient pain control received an ESP block and were assigned to Group II. Blood samples were collected at baseline, after treatment response, and at the three-month follow-up. T‑cell subsets and natural killer (NK) cell subgroups were analyzed using flow cytometry. Pain intensity, sleep interference, and PHN incidence were evaluated during follow-up.ResultsPain and sleep interference scores improved significantly over time in both groups (P < 0.05).The incidence of PHN did not differ significantly between the groups. However, at the three-month follow-up, patients in the ESP block group, who were receiving higher pregabalin doses, demonstrated lower CD3⁺ and CD4⁺ T-cell levels and reduced NK cell subset levels compared with Group I (P < 0.05).Baseline NK CD56 Bright levels were significantly higher in patients who did not develop PHN (P < 0.05).ConclusionAlthough the ESP block did not reduce the incidence of PHN, immunological differences were observed between the treatment groups during follow-up. Higher baseline NK CD56 Bright levels in patients who did not develop PHN suggest a potential protective association between preserved NK-cell–mediated immunity and resistance to pain chronification following herpes zoster.Keywords: postherpetic neuralgia, herpes zoster, erector spinae plane block, neuropathic pain, immune system phenomena, natural killer cells Introduction Postherpetic neuralgia (PHN) is a persistent and treatment-resistant pain syndrome that represents one of the most clinically significant complications of herpes zoster.1 In addition to pharmacological therapies, interventional techniques have demonstrated efficacy in the management of herpes zoster–related pain and are now widely incorporated into routine clinical practice. Pregabalin remains one of the most commonly used pharmacological agents in this context. Pregabalin was selected as the initial pharmacological treatment because it is recommended as a first-line agent for neuropathic pain and is routinely used in the clinical management of herpes zoster–related pain. In addition, a previous work has suggested that pregabalin may influence T-cell polarization and immune regulation, further supporting its relevance within the immunological framework of the present study.2 However, the erector spinae plane (ESP) block, despite being a relatively recently described technique, has rapidly emerged as a widely utilized interventional approach.3,4 Recent studies have highlighted the critical role of the immune system in the pathogenesis of neuropathic pain.5 Regional anesthesia techniques are increasingly recognized not only for their analgesic effects but also for their capacity to modulate systemic inflammatory and neuroimmune responses by reducing nociceptive afferent signaling and stress-related cytokine release. Previous studies have demonstrated that ESP block may reduce circulating inflammatory mediators, suggesting a potential immunomodulatory effect.6–8 However, to date, no clinical studies have specifically evaluated the effects of interventional analgesic techniques on immune cell profiles, particularly natural killer (NK) cell subsets and T-cell polarization, in patients with herpes zoster. The selected immunological markers, including T-cell subsets, regulatory T cells (Treg), T helper (Th) 17-related markers and NK cell subsets, were chosen based on previous clinical and experimental studies implicating adaptive and innate immune dysregulation in neuropathic pain development and PHN pathophysiology.2,9–13 We therefore hypothesized that ESP block applied in patients with inadequate response to pregabalin therapy may modulate immune cell profiles associated with neuropathic pain and may influence the development of PHN. Accordingly, we designed this study to evaluate immune cell profiles that are most commonly implicated in the pathophysiology of neuropathic pain. The primary outcomes of the study were changes in immunological marker levels and the incidence of PHN. Secondary outcomes included changes in pain intensity, sleep quality, and the requirement for additional analgesic therapy. Materials and Methods The study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Necmettin Erbakan University Meram Faculty of Medicine Clinical Research Ethics Committee (Decision No:2021/637) and Clinical Research Ethics Committee of the Turkish Medicines and Medical Devices Agency (Approval date: 17/11/2021 and numbered E-66175679-514.04.01–596,461). It was also registered with the Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12624001149550). The study was designed as a prospective, controlled, single-blind, non-randomized study and was conducted on 30 patients at an academic university hospital between October 2024 and June 2025. Owing to the single-blind design, the investigator performing the ESP block was not involved in routine outpatient follow-up, pain assessments, or treatment planning. Patients were aware of their treatment allocation; however, the investigator responsible for follow-up assessments, including Numeric Rating Scale (NRS), Douleur Neuropathique 4 (DN4) score, and Sleep Interference Score (SIS) recordings, remained blinded to group assignment throughout the study. Patients aged 18–80 years with a diagnosis of herpes zoster were eligible for inclusion if they had completed the acute phase of the disease, presented with crusted vesicular lesions, had completed antiviral therapy, and demonstrated thoracic dermatomal involvement. Additional inclusion criteria included a DN4 score ≥4, no prior treatment for neuropathic pain, and absence of established chronic pain. Exclusion criteria included diabetes mellitus, alternative causes of neuropathic pain, malignancy, prior treatment for neuropathic pain, bacterial infection at the affected dermatome, autoimmune disease, drug or alcohol dependence, smoking history, chronic renal or hepatic failure, immunodeficiency, pregnancy, lactation, and refusal to participate. Pregabalin therapy was initiated at the initial visit in all eligible patients. Patients whose pain was adequately controlled with an appropriate dose of pregabalin (NRS score <4) were assigned to Group I. Patients whose pain remained uncontrolled (NRS ≥4) despite appropriate dose titration underwent ESP block and were assigned to Group II. Group Allocation and Treatment Protocol Patients were managed according to a predefined stepwise treatment algorithm (Figure 1). Initial pregabalin dosing was individualized according to a predefined clinical protocol based on patient age, frailty status, comorbidities, concomitant medication use, and anticipated tolerability. Patients considered at increased risk for adverse effects, particularly elderly or clinically frail individuals, were initiated on 25 mg twice daily, whereas younger patients with preserved functional status and no major contraindications were initiated on 75 mg twice daily. Treatment response was assessed using the NRS at scheduled outpatient visits, and dose adjustments were performed according to the predefined protocol until an adequate analgesic response (NRS <4) or the maximum planned pregabalin dose was reached. Patients who achieved adequate pain control during the dose-titration phase and maintained symptom control without requiring interventional treatment were assigned to Group I. Patients who remained symptomatic despite optimized pregabalin therapy were assigned to Group II and underwent an ESP block. Clinical response following ESP block was reassessed within 24 hours. During follow-up, patients in both groups were evaluated at 2-week intervals. In cases of insufficient analgesia (NRS ≥4), treatment escalation was performed according to the predefined multimodal analgesic protocol, including stepwise pharmacological rescue therapy. Patients who failed to achieve adequate pain control despite maximal medical treatment, required additional interventional procedures, or could not tolerate treatment because of adverse effects were excluded from the study. At each follow-up NRS, DN4, and SIS were recorded. The final study visit was performed at the end of the third month after study enrollment. Because enrollment occurred only after completion of the acute phase of herpes zoster, this assessment was performed beyond 90 days after rash onset in all patients. Persistent pain at this visit was defined as PHN. Group Allocation and Treatment Protocol Diagram. ESP Block Procedure The ESP block was performed at the dermatome level corresponding to the affected thoracic region. In cases involving multiple dermatomes, the block was performed at the midpoint of the involved region. Patients were placed in the prone position, and skin preparation was performed using 10% povidone-iodine. Local anesthesia of the skin and subcutaneous tissue was achieved with 3 mL of 2% lidocaine hydrochloride. Under ultrasound guidance, using a linear probe operating at 8 MHz (Esaote MyLab Six CrystaLine, Genoa, Italy) covered with a sterile sheath, the thoracic vertebral spinous process was first visualized in the horizontal plane at the midline. The probe was then rotated into the longitudinal plane to visualize the transverse process and the erector spinae muscle approximately 3 cm lateral to the midline. A 22-gauge, 80-mm block needle (Sonoplex®, Pajunk Medical, Geisingen, Germany) was advanced in-plane in a cranio-caudal direction. Correct needle placement between the erector spinae muscle and the transverse process was confirmed using hydrodissection. A total volume of 20 mL of 0.375% bupivacaine hydrochloride was injected, and a single ESP block was performed for each patient as specified in the study protocol. The spread of the local anesthetic was visualized in real time using ultrasonography. Thirty minutes after the block, loss of cold and warm sensation above and below the targeted dermatome was accepted as successful block performance. Patients with unsuccessful blocks were excluded from the study. Surface Staining, Cell Culture, and Flow Cytometric Analysis Peripheral blood samples were collected from all patients at baseline. In Group I, second blood samples were obtained at the first follow-up visit at which a clinical response to pregabalin therapy was confirmed and the dose was stabilized. In Group II, second samples were collected 24 hours after ESP block administration. A third set of blood samples was obtained from all patients at the end of the three-month follow-up period.The collected samples were analyzed to determine the levels of Th cells, cytotoxic T cells, Treg, and NK cell subsets. Venous blood (5 mL) was obtained preferentially from the antecubital (brachial) vein using a tourniquet under aseptic conditions and collected into tubes containing ethylenediaminetetraacetic acid (EDTA). Peripheral blood mononuclear cells were isolated from the samples. Surface staining was performed using monoclonal antibodies obtained from Becton Dickinson (BD, USA). Cells were incubated in the dark for 20 minutes, followed by fixation and permeabilization using BD Perm/Wash buffer. Intracellular staining was subsequently performed using BD antibodies according to the manufacturer’s protocol. Flow cytometric analysis was carried out using a BD FACS Canto II flow cytometer (Becton Dickinson, USA). All biological materials were handled and disposed of in accordance with institutional biosafety regulations. Statistical Analysis A total of 30 patients were included in the study, with 15 patients allocated to each group. The sample size was determined a priori based on the targeted patient population and resource considerations. As the study was not designed as a randomized controlled trial, a formal power analysis was not performed. Statistical analyses were conducted using SPSS software (version 21.0; IBM Corp., Armonk, NY, USA). Descriptive statistics were presented as mean ± standard deviation or median with interquartile range (IQR), as appropriate. The Hodges–Lehmann estimator was used to calculate 95% confidence intervals for median differences. Categorical variables were expressed as counts and percentages (n [%]) and analyzed using the chi-square test or Fisher’s exact test, as appropriate. Normality and homogeneity of variances were assessed using the Shapiro–Wilk and Levene tests, respectively. For comparisons of continuous variables, the independent-samples t-test was used for normally distributed data, whereas the Mann–Whitney U-test was applied for non-normally distributed variables. Repeated measures were analyzed using the Friedman test, and pairwise comparisons with baseline values were performed using the Wilcoxon signed-rank test with Bonferroni correction. Between-group comparisons of immunological markers were considered exploratory because no formal adjustment for multiple comparisons was applied across individual biomarkers. A two-sided P value < 0.05 was considered statistically significant. Results A total of 30 patients who met the inclusion criteria were enrolled in the study, and no participants were excluded (Figure 2). The baseline demographic characteristics were comparable between the two groups (Table 1). Flow Diagram of the Study. Table 1Baseline Demographic CharacteristicsVariableGroup I (n=15)Group II (n=15)PAge (years)63.40 ± 14.8263.73 ± 9.380.775Sex (male/female)6/94/110.539BMI (kg/m2)28.25 ± 4.8228.22 ± 3.570.775Notes: Values are presented as mean ± standard deviation.Abbreviation: BMI, body mass index. Baseline Demographic Characteristics Notes: Values are presented as mean ± standard deviation. Abbreviation: BMI, body mass index. In both groups, significant reductions in NRS, DN4 and SIS values were observed over time (P < 0.001) (Figure 3). When pregabalin dose requirements were compared between the groups, patients in Group II required significantly higher doses than those in Group I at the final follow-up visit (P < 0.001) (Figure 3). Additional analgesic use was observed in 8 patients in Group I and 5 patients in Group II, with no statistically significant difference between the groups (P = 0.367) (Table 2). Changes in NRS, DN4, SIS, and Pregabalin Consumption Over Time. (A) NRS over follow-up. (B) DN4 over follow-up. (C) SIS over follow-up. (D) Pregabalin dose requirement. Table 2Pregabalin Dose and Additional DrugsVariableGroup I(n=15)Group II(n=15)PInitial pregabalin (25 mg 2×1)5(33.3%)4(26.7%)1.000Initial pregabalin (75 mg 2×1)10(66.7%)11(73.3%)1.000Tramadol/paracetamol8(53.3%)5(33.3%)0.462High dose tramadol0(0%)0(0%)NAOxycodone0(0%)0(0%)NANotes: Values are presented as n (%).Abbreviations: mg, milligram; NA, not applicable. Pregabalin Dose and Additional Drugs Notes: Values are presented as n (%). Abbreviations: mg, milligram; NA, not applicable. Within-group changes in immunological markers across the three time points revealed that interleukin(IL)-17A and NK cluster of differentiation(CD) 57 levels increased significantly over time in Group I (P = 0.015 and P = 0.011, respectively). In Group II, forkhead box P3 (FOXP3) levels exhibited a biphasic pattern, initially increasing and subsequently decreasing, indicating a significant time-dependent variation (P = 0.008) (Table 3). No statistically significant changes in the Th17/Treg ratio were observed either within or between groups at any time point (P > 0.05). Table 3Comparison of Immunological Markers Between Groups1st Measurement2nd Measurement3rd MeasurementGroup I (n: 15)Group II (n: 15)PGroup I (n: 15)Group II (n: 15)PGroup I (n: 15)Group II (n: 15)PCD4+ T cells (%)31.7±11.431.2±12.70.62434.1±10.624.0±15.00.50037.0±12.425.3±12.80.026CD3+ T cells (%)52.5±14.548.8±16.90.62454.8±13.941.2±23.10.12658.6±17.142.1±17.70.033CD8+ T cells (%)20.7±9.117.5±10.20.59520.6±6.117.2±11.60.46121.6±9.716.8±9.60.161FOXP3 (Treg) (%)6.5±2.05.1±2.70.0616.8±5.87.1±2.50.2026.8±2.16.8±2.80.806NK Defective Subset (%)10.2±9.617.4±22.40.7449.3±8.919.0±24.50.32514.9±10.69.0±15.00.023NK Regulatory Subset (%)4.9±3.29.8±13.80.8066.3±5.34.5±4.60.2857.1±6.92.4±1.70.010NK Cytotoxic Subset (%)18.1±12.720.2±14.20.68320.6±13.821.1±18.50.90227.8±14.315.6±11.90.021NK CD57 (%)11.8±7.715.0±12.30.62411.5±8.216.5±16.70.43617.3±6.810.4±7.80.005NK CD56 Bright (%)2.7±2.13.1±1.90.5674.7±3.93.2±2.50.3893.7±2.71.5±1.70.002NK CD56 Dim (%)19.1±12.518.8±12.30.90219.3±12.018.5±17.30.59527.1±12.117.8±16.10.041IFN-γ+ T cells (%)5.7±2.78.1±5.60.2679.5±8.58.7±5.70.5679.7±5.99.6±5.30.713IL17A+ T cells (%)1.6±0.82.4±2.10.4862.1±1.71.6±1.60.2853.3±1.93.2±3.00.305Notes: Values are presented as mean± standard deviation. Bold P values indicate P<0.05.Abbreviations: CD, cluster of differentiation; FOXP3, forkhead box P3; Treg, regulatory T cell; NK, natural killer; IFN-γ, interferon gamma; IL,interleukin. Comparison of Immunological Markers Between Groups Notes: Values are presented as mean± standard deviation. Bold P values indicate P<0.05. Abbreviations: CD, cluster of differentiation; FOXP3, forkhead box P3; Treg, regulatory T cell; NK, natural killer; IFN-γ, interferon gamma; IL,interleukin. Exploratory between-group comparisons of immunological marker levels demonstrated that, at the three-month follow-up, levels of CD3, CD4, NK defective, regulatory, and cytotoxic subsets, as well as NK CD57, NK CD56 Bright, and NK CD56 Dim cells, were significantly lower in Group II (Figure 4). Between-group comparison of immune markers at the third measurement. When the development of PHN was evaluated, PHN occurred in 6 patients in Group I and 4 patients in Group II, with no statistically significant difference between the groups (P = 0.699; OR, 1.83; 95% CI, 0.39–8.56). Stratification of patients into PHN-positive and PHN-negative groups revealed no significant differences in baseline demographic characteristics. At the final outpatient visit, NRS, DN4 and SIS values were significantly higher in patients who developed PHN (P = 0.004, P = 0.009, and P = 0.008, respectively). With respect to immunological markers, CD3⁺ and CD8⁺ T-cell levels at the third measurement were significantly higher in patients who developed PHN (P = 0.043 and P = 0.022, respectively). In contrast, baseline NK CD56 Bright levels were significantly higher in patients who did not develop PHN (P = 0.035). Although a numerical increase in the Th17/Treg ratio was observed at the final follow-up in patients who developed PHN, this difference did not reach statistical significance (Table 4). Table 4Comparison of Th17/Treg Ratio,CD4⁺/CD8⁺ Ratio and NK CD56 Bright Cell Levels According to PHN Development1st Measurement2nd Measurement3rd MeasurementPPHN Developed (n: 10)Th17/Treg0.45 ± 0.720.30 ± 0.300.66 ± 0.640.211CD4⁺/CD8⁺1.65 ± 0.911.67 ± 0.821.70 ± 0.890.950NK CD56 Bright (%)2.39 ± 2.083.12 ± 2.632.96 ± 2.430.744PHN Not Developed (n: 20)Th17/Treg0.49 ± 0.490.43 ± 0.470.50 ± 0.380.558CD4⁺/CD8⁺3.31 ± 2.902.10 ± 1.042.45 ± 1.690.370NK CD56 Bright (%)3.75 ± 1.725.28 ± 4.012.11 ± 2.630.205PTh17/Treg0.3200.9160.783CD4⁺/CD8⁺0.0660.3900.086NK CD56 Bright (%)0.0350.1220.175Notes: Values are presented as mean± standard deviation. Bold P values indicate P<0.05.Abbreviations: PHN, postherpetic neuralgia; Treg, regulatory T cell; Th17, T helper 17 cell; CD, cluster of differentiation; NK, natural killer. Comparison of Th17/Treg Ratio,CD4⁺/CD8⁺ Ratio and NK CD56 Bright Cell Levels According to PHN Development Notes: Values are presented as mean± standard deviation. Bold P values indicate P<0.05. Abbreviations: PHN, postherpetic neuralgia; Treg, regulatory T cell; Th17, T helper 17 cell; CD, cluster of differentiation; NK, natural killer. Discussion In this study, we evaluated the effects of adding an ESP block to pregabalin therapy on PHN incidence and immunological marker profiles in patients with painful herpes zoster who were unresponsive to pregabalin therapy. Significant reductions in CD3⁺ and CD4⁺ T cells, as well as NK-cell subgroups, were observed at the three-month follow-up in patients who received an ESP block. Although the ESP block did not reduce PHN incidence, baseline NK CD56 Bright levels were notably higher in patients who did not develop PHN. PHN is one of the most prevalent causes of peripheral neuropathic pain and is associated with substantial impairment in quality of life.14 Increasing evidence suggests that the adaptive immune response plays a critical role in the pathogenesis of neuropathic pain; however, current data remain limited and clinical evidence is still insufficient.9,15 During neuropathic pain development, CD3⁺, CD4⁺, and CD8⁺ T cells infiltrate affected neural tissues and contribute to neuroinflammatory processes, while elevated CD8⁺ T-cell levels have also been demonstrated in cerebrospinal fluid samples from patients with PHN.16 Paradoxically, despite increased local immune cell infiltration, patients with PHN exhibit reduced systemic cell-mediated immunity, primarily characterized by T-cell dysfunction. Previous clinical studies have demonstrated dynamic alterations in CD3⁺, CD4⁺, and CD8⁺ T-cell subsets during herpes zoster progression, with reduced CD4⁺ T-cell levels being particularly associated with PHN development.2,10–12 Despite these heterogeneous findings, the overall body of evidence supports a pivotal role for T cells in the development and maintenance of PHN. In our cohort, patients who received an ESP block exhibited significantly lower CD3⁺ and CD4⁺ T-cell levels at the three-month follow-up. When PHN development was evaluated, no differences were observed in CD4⁺/CD8⁺ ratios; however, CD3⁺ and CD8⁺ T-cell levels at the three-month follow-up were significantly higher in patients who developed PHN. These findings suggest that persistent T-cell–mediated immune activation may contribute to PHN development. Although the ESP block did not reduce PHN incidence, it appeared to attenuate this immune activation when combined with pregabalin therapy. Importantly, previous clinical work from our institution demonstrated that pregabalin itself may influence T-cell polarization, particularly through increased Th17-related immune activity.2 Therefore, the immunological changes observed in the present study likely reflect the combined effects of ESP block, pregabalin exposure, and the natural immunological course of herpes zoster rather than the isolated effect of ESP block alone. Nevertheless, definitive conclusions require validation in larger cohorts with more comprehensive immunological profiling. Alterations in the Th17/Treg balance have attracted increasing interest in neuropathic pain research, as disruption of this balance may contribute to pain chronification through altered T-cell polarization.9,17 In herpes zoster, elevated Treg levels have also been suggested to facilitate PHN development by suppressing antiviral CD4⁺ T-cell responses,18 while pregabalin has been reported to influence Th17-related immune activity.2 In the current analysis, Th17 levels increased significantly over time in Group I, whereas this increase was not observed in Group II. Treg levels remained stable in Group I but showed transient fluctuations in Group II. However, no statistically significant differences in the Th17/Treg ratio were observed either within or between groups. Therefore, these findings should be considered exploratory and interpreted with caution. Similarly, no statistically significant differences in Th17, Treg, or Th17/Treg ratios were observed according to PHN development, although a numerical increase in the final Th17/Treg ratio was noted in patients who developed PHN, the clinical significance of which remains uncertain. In addition, peripheral blood measurements may not fully reflect the localized neuroimmune interactions occurring within the dorsal root ganglion, spinal dorsal horn, or affected peripheral nerves, where neuropathic pain-related inflammatory processes are believed to occur.5,19 Further studies incorporating larger cohorts and more comprehensive neuroimmune assessments are needed to better clarify the role of Th17/Treg polarization in PHN development. NK cells are effector and regulatory immune cells that eliminate virus-infected and malignant cells through cytokine production and cytotoxic activity.13 Previous studies have reported altered NK-cell activity in both acute herpes zoster and PHN, while reduced NK-cell function has been associated with increased susceptibility to viral reactivation in immunocompromised populations.11,20 The present findings demonstrated that baseline NK CD56 Bright levels were significantly higher in patients who did not develop PHN. This finding represents one of the most clinically relevant immunological observations of our study. CD56 Bright NK cells are specialized immunoregulatory cells involved in antiviral immunity, immune surveillance, and modulation of neuroinflammatory responses. Therefore, higher baseline CD56 Bright NK-cell levels may reflect more preserved antiviral immune capacity in patients who do not develop PHN. Importantly, this association was observed before any treatment intervention, suggesting that baseline CD56 Bright NK-cell levels may represent not merely a marker of immune status, but a potential early biomarker of resistance against PHN development. Previous studies have demonstrated that opioid exposure may lead to modest reductions in CD56 Bright levels without affecting CD56 Dim subsets or overall NK-cell function, whereas there is currently no evidence suggesting that pregabalin exerts suppressive effects on NK-cell activity.21 Although significant between-group differences in NK-cell subsets were observed at the final follow-up in the ESP block group, no significant longitudinal within-group changes were detected, and the clinical relevance of these findings remains uncertain. Given the limited sample size and differential pregabalin exposure between groups, these observations should be interpreted cautiously. Therefore, further studies are needed to clarify the independent and combined effects of ESP block and pregabalin therapy on NK-cell function. The ESP block is a fascial plane block targeting the dorsal and ventral rami of spinal nerves and has demonstrated clinical efficacy in the management of herpes zoster–related pain.4,22 However, insufficient clinical data exist regarding its effect on PHN development. Nerve blocks are known to attenuate systemic inflammatory responses by reducing nociceptive input, and the ESP block has similarly been associated with reduced circulating inflammatory cytokine levels in thoracic surgical settings.6–8 The precise mechanisms underlying the ESP block remain incompletely understood. Experimental studies have demonstrated dye accumulation in prevertebral thoracic lymph nodes even in the absence of paravertebral spread, raising the hypothesis that lymphatic-mediated immunomodulation may represent one possible mechanism of action of the ESP block.23 Experimental studies have suggested that lymphatic transport may facilitate neuroimmune modulation, and capsaicin administration into lymph nodes has been shown to reduce neurogenic inflammation and pain in experimental models.24,25 However, direct clinical evidence supporting this mechanism in patients receiving ESP block remains limited. Our findings demonstrated significant between-group differences in CD3⁺ and CD4⁺ T-cell levels and NK-cell subsets at the three-month follow-up. However, these findings should be interpreted with caution, as patients in Group II had insufficient pain control with pregabalin alone and were receiving higher pregabalin doses at the same time point. Therefore, the observed immunological differences cannot be attributed solely to the ESP block and may reflect the combined effects of treatment refractoriness, greater pregabalin exposure, and ESP block application. To date, no studies have specifically evaluated the effects of ESP block on immune cell populations, particularly NK cells. Although a causal relationship cannot be confirmed, our findings suggest a possible association between ESP block application and alterations in NK-cell profiles. From a clinical perspective, our findings do not support routine use of ESP block for prevention of PHN in all patients with herpes zoster. However, in patients who fail to achieve adequate pain control despite optimized pregabalin therapy, ESP block may represent a valuable adjunctive strategy, not only for symptomatic pain management but also for potential modulation of neuroimmune responses. Although a direct reduction in PHN incidence was not demonstrated in this study population, the observed immunological changes suggest that ESP block may influence biological pathways involved in pain chronification. Therefore, rather than replacing pharmacological treatment, ESP block may currently be considered as a complementary option in selected refractory cases until larger randomized trials establish its optimal timing and clinical indications. This study has several important limitations. First, this study was not designed as a randomized controlled trial, and no formal power analysis was performed during study planning. Consequently, the relatively small sample size may have limited statistical power to detect clinically meaningful differences in PHN incidence, increasing the risk of type II error for this primary outcome. In addition, simultaneous evaluation of multiple immunological markers in a limited cohort may increase the risk of type I error in exploratory comparisons. Therefore, both clinical and immunological findings should be interpreted with appropriate caution. Moreover, although Bonferroni correction was applied for within-group pairwise comparisons, between-group comparisons of multiple immunological markers were not adjusted for multiple testing. Therefore, some statistically significant between-group findings should be interpreted as exploratory observations with an increased risk of type I error. Second, because group allocation was determined by clinical response to pregabalin rather than randomization, patients in the ESP block group inherently represented individuals with insufficient pain control under initial pharmacological therapy. In addition, all patients who underwent ESP block were concurrently receiving higher doses of pregabalin during follow-up. Consequently, the independent effects of ESP block on immunological markers and clinical outcomes cannot be clearly delineated, and the observed between-group immunological differences may reflect the combined effects of treatment refractoriness, greater pregabalin exposure, and ESP block application. In addition, the second immunological assessment was performed at different clinically defined time points between groups, reflecting treatment response confirmation in Group I and 24-hour post-intervention assessment in Group II. This temporal asymmetry may have influenced intermediate longitudinal comparisons and should be considered when interpreting second-time point findings. Although additional analgesic requirements during follow-up were limited and comparable between groups, the potential immunomodulatory effects of concomitant analgesic treatments cannot be completely excluded and may have influenced the longitudinal immunological measurements. Third, immunological assessments were based on peripheral blood samples, which may not accurately reflect local inflammatory and immune processes at the level of the dorsal root ganglion or the affected dermatomes. In addition, the follow-up period was limited to three months, precluding evaluation of long-term outcomes. Finally, the absence of a healthy control group limited our ability to distinguish the isolated effects of herpes zoster infection and its treatment on immunological marker profiles. Conclusion The present study demonstrates that the ESP block applied in herpes zoster patients with inadequate response to pregabalin therapy does not significantly reduce the incidence of PHN. However, the observed immunological changes in patients receiving ESP block may reflect the combined effects of ESP block application and higher pregabalin exposure rather than an isolated effect of the intervention. Notably, higher baseline NK CD56 Bright levels observed in patients who did not develop PHN suggest that this cellular subset may serve as a potential protective biomarker against chronic neuropathic pain. Although a direct effect of the ESP block on PHN incidence could not be established, it may represent a complementary therapeutic option in selected refractory patients. Further large-scale, randomized controlled studies with extended follow-up are warranted to validate these findings. Acknowledgments The authors thank Şeyma Çelikbilek Çelik for her support during the studies conducted in the allergy and immunology laboratory. Funding Statement This study was funded by the Scientific Research Projects Coordinatorship of the University (Project No: 211218018). Data Sharing Statement All shared data will be fully deidentified to protect participant privacy and confidentiality. The data and study documents will be available for 5 years from the date of the manuscript’s publication, and can be accessed by contacting the corresponding author at Gülçin Büyükbezirci (drgulcin81@gmail.com). No additional ethical approval is required for data reuse, in line with the original study’s ethical approval. Ethical and Consent Statements This study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Necmettin Erbakan University Meram Faculty of Medicine Clinical Research Ethics Committee (Decision No:2021/637) and Clinical Research Ethics Committee of the Turkish Medicines and Medical Devices Agency (Approval date: 17/11/2021 and numbered E-66175679-514.04.01-596461). It was also registered with the Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12624001149550). Informed written consent was obtained from all eligible participants prior to their enrollment in the study, and all participants were informed of their right to withdraw from the study at any time without penalty. Author Contributions Gülçin Büyükbezirci,Numan Demiralp,Sevgi Keleş and Ruhiye Reisli contributed to the conception and design of the study and drafted the manuscript. Numan Demiralp, Resul Yılmaz, and Şule Arıcan were responsible for data collection and statistical analysis. All authors made a significant contribution to the work reported, whether in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure Gülçin Büyükbezirci is the first author of this study. The authors declare no potential conflicts of interest related to this study. References Associated Data Data Availability Statement All shared data will be fully deidentified to protect participant privacy and confidentiality. The data and study documents will be available for 5 years from the date of the manuscript’s publication, and can be accessed by contacting the corresponding author at Gülçin Büyükbezirci (drgulcin81@gmail.com). No additional ethical approval is required for data reuse, in line with the original study’s ethical approval.